Valuation: Dechra Pharmaceuticals

Capitalization 4.4B 5.97B 5.06B 4.65B 8.16B 552B 8.3B 54.49B 21.37B 268B 22.39B 21.93B 944B P/E ratio 2022
64.8x
P/E ratio 2023 -150x
Enterprise value 4.83B 6.55B 5.55B 5.11B 8.96B 606B 9.12B 59.82B 23.45B 294B 24.58B 24.07B 1,036B EV / Sales 2022
5.8x
EV / Sales 2023 6.08x
Free-Float
-
Yield 2022
1.3%
Yield 2023 0.34%
3 years 3,060
Extreme 3060
4,145.84
5 years 2,473.32
Extreme 2473.323
5,525
10 years 811
Extreme 811
5,525
Manager TitleAgeSince
Director of Finance/CFO 46 2019-04-02
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 2022-06-30
Director TitleAgeSince
Director/Board Member 46 2019-10-29
Director/Board Member 68 2016-11-30
Director/Board Member 59 2019-01-31

Financials

2022 2023
Net sales 682M 924M 783M 720M 1.26B 85.52B 1.29B 8.44B 3.31B 41.46B 3.47B 3.39B 146B 762M 1.03B 874M 805M 1.41B 95.52B 1.44B 9.42B 3.7B 46.3B 3.87B 3.79B 163B
Net income 58.2M 78.9M 66.83M 61.49M 108M 7.3B 110M 720M 282M 3.54B 296M 290M 12.47B -27.9M -37.82M -32.04M -29.48M -51.71M -3.5B -52.62M -345M -135M -1.7B -142M -139M -5.98B
Net Debt 208M 282M 239M 220M 386M 26.12B 393M 2.58B 1.01B 12.66B 1.06B 1.04B 44.62B 430M 583M 494M 454M 797M 53.95B 811M 5.32B 2.09B 26.15B 2.19B 2.14B 92.18B
Logo Dechra Pharmaceuticals
Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).
Employees
-
Sector
-